Fortis Healthcare Limited — PPTs, 07-02-2025: Investor Presentation

Fortis Healthcare reported robust Q3 FY25 results, with consolidated revenues increasing 14.8% year-on-year to INR 1,928 Cr. Operating EBITDA rose significantly by 32.0%, reaching INR 375 Cr, with a margin improvement to 19.4% compared to 16.9% in Q3 FY24. The hospital segment contributed substantially, with revenue up 16.8% at INR 1,623 Cr and an operating EBITDA margin of 20.0%. Notably, Fortis consolidated its stake in Agilus Diagnostics from 57.68% to 89.20%, bolstering its position in the diagnostics market.

Looking ahead, the focus on improving profitability through strategic divestitures, such as the recent sale of the Richmond Road facility, aligns with efforts to enhance overall margins. The company’s expanding digital channels and increased international patient revenues indicate a positive trajectory, while the diagnostic arm is gradually recovering, evidenced by a 5.2% revenue growth year-on-year. Overall, Fortis maintains a positive outlook as operational performance strengthens across its core healthcare services, alongside cost efficiencies.

Watch closely as Fortis continues to leverage its integrated healthcare model for sustainable growth.